FDA warned TKTX USA that its TKTX Numbing Creams are unapproved and misbranded drugs with lidocaine levels above OTC limits.
What happened
FDA reviewed TKTX USA's product labeling on www.tktxusa.com and its Facebook and Instagram handles. It found the five TKTX Numbing Creams offered for sale without a prescription as external analgesics for cosmetic procedures, with labeled lidocaine concentrations of 20%, 25%, 35%, and 40% and some products containing prilocaine and/or epinephrine. FDA said these formulas and intended uses do not meet the OTC external analgesic monograph, making the products unapproved and misbranded.
What FDA found
The creams are unapproved new drugs because they are sold without an FDA-approved application and do not qualify for over-the-counter marketing under the relevant OTC rules.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)The creams are misbranded because they are nonprescription drugs that do not meet the OTC marketing requirements and lack an approved application.
FD&C Act section 502(ee), 21 U.S.C. 352(ee); section 301(a), 21 U.S.C. 331(a)The labels state lidocaine concentrations of 20%, 25%, 35%, and 40% for the variants, above the 0.5% to 4% range allowed for over-the-counter external analgesics.
OTC Monograph M017; FD&C Act section 505G, 21 U.S.C. 355hSome products combine lidocaine with prilocaine and/or epinephrine, which are not permitted active ingredients in the external analgesic OTC monograph; prilocaine is not permitted in any final OTC order.
OTC Monograph M017; FD&C Act section 505G, 21 U.S.C. 355hThe labels promote use for tattooing, piercing, and laser cosmetic procedures, which are not allowed indications for OTC external analgesics.
OTC Monograph M017; FD&C Act section 505G, 21 U.S.C. 355h
What FDA wants
FDA asks TKTX USA to respond in writing within 15 working days with the steps it has taken to correct the violations, how it will prevent them from recurring, and supporting documents. If it cannot finish, it must explain the delay and give a completion date.
Who should pay attention
- tattoo and cosmetic procedure providers who use numbing creams
- online sellers and distributors of topical anesthetics
- consumers who buy numbing creams without a prescription
This is a summary. Read the original letter on fda.gov.